|
|
The Journal of Vascular Surgery (J Vasc Bras.) is a peer-reviewed quarterly publication of the Brazilian Society of Angiology and Vascular Surgery (Sociedade Brasileira de Angiologia e de Cirurgia Vascular - SBACV). It is directed to vascular surgeons and clinicians and to professionals of related fields, and accepts submissions in Portuguese, English, and Spanish. The mission of the Journal is to select and disseminate high quality scientific contents concerning original research, novel surgical and diagnostic techniques, and clinical observations in the field of vascular surgery, angiology, and endovascular surgery, as well as reviews and case reports.
I. EDITORIAL POLICY AND PEER REVIEW
II. CONFLICT OF INTEREST, HUMAN AND ANIMAL RIGHTS, AND INFORMED CONSENT
III. MANUSCRIPT PREPARATION AND SUBMISSION
IV. PUBLICATION CHARGES AND CONTACT INFORMATION
V. COPYRIGHT AND PUBLICATION LICENSE AGREEMENT
I. EDITORIAL POLICY AND PEER REVIEW
J Vasc Bras. follows the recommendations found in the latest version of the Uniform Requirements for Manuscripts Submitted to Biomedical Journals (ICMJE). The complete document is available at www.icmje.org.
J Vasc Bras. follows the ethical principles found in the Committee on Publication Ethics (COPE) code of conduct (http://publicationethics.org/resources/code-conduct) with regard to duplicate publication, plagiarism, fabricated data, addition or removal of authors, ghost or gift authorship, undisclosed conflict of interest, ethical problems in the study, undue appropriation of ideas or data, response to rumors of misconduct via any media.
Manuscripts that are not in accordance with this instructions will be returned to the authors for correction before review by the Editorial Board.
1. Originality - Manuscripts submitted for publication should not have been published nor been submitted for evaluation to other journals in part or in whole.
2. Copyright - All accepted manuscripts in J Vasc Bras. except when otherwise stated are published as Full Open Access articles and are freely distributed under the terms of the Creative Commons Attribution License (CC-BY), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. All Authors retain copyright for articles published under this license and are required to submit a Copyright and Publication License Agreement, described below. Articles including previously published figures or other material should cite the original source in the corresponding legends and written permission must be obtained from the copyright holder. We recommend that authors keep a copy of the materials submitted to J Vasc Bras., since they will not be returned to authors.
3. Editorials - These papers will have a scientific nature. - J Vasc Bras. will not consider editorials which were not invited by the Editor-in-Chief or which have commercial purposes.
4. Decision-making process - Manuscript receipt will be acknowledged via an automatic e-mail message generated by the submission system (http://mc04.manuscriptcentral.com/jvb-scielo). If the paper is in accordance with this Instructions to Authors and with the editorial policies of the Journal, it will be reviewed by two referees assigned by the Editor-in-Chief. The process will proceed as follows:
Author Submits
Admin Checks and Passes to EIC (Editor-in-Chief)
Editor-in-Chief Invites and/or Assigns Reviewer(s)
Reviewers Score
Editor-In-Chief Makes Final Decision
Authors and reviewers will remain anonymous throughout the review process. Within 60 days, the authors are informed of either acceptance, rejection, or the need for revisions in the article, as requested by the Editorial Board. A decision letter and reviewers’ comments will be e-mailed to the authors. Authors will be requested to return a revised version of the manuscript within 1 month and to provide a letter detailing their responses to the reviewers’ comments. Revised manuscripts should clearly indicate changes made to the text, using red font preferably. Revised manuscripts will be sent back to reviewers for reassessment. At this time, a decision will be taken for the acceptance, rejection, or the need for additional revisions.
Below, we disclose the Assessment Questionnaire to the general public, so as to ensure total transparency of the editorial process.
• Does the manuscript contain new and significant information to justify publication?
• Does the Abstract (Summary) clearly and accurately describe the content of the article?
• Is the problem significant and concisely stated?
• Are the methods described comprehensively?
• Are the interpretations and conclusions justified by the results?
• Is adequate reference made to other work in the field?
• Is the language acceptable?
• Please rate the priority for publishing this article (1 is the highest priority, 10 is the lowest priority).
• Manuscript Structure: Is the length of the article, number of tables and figures adequate? Too short/ few? Too long/many?
• Please state any conflict(s) of interest that you have in relation to the review of this paper (state “none” if this is not applicable).
• Please rate the article for Interest, Quality, Originality, and Overall, choosing between Excellent, Good, Average, Below Average, or Poor.
• Confirm that the study was approved by an Ethics Committee.
• Recommendation: Accept, Minor Revision, Major Revision, Reject & Resubmit, or Reject.
• Would you be willing to review a revision of this manuscript?
5. Authorship - A maximum of eight authors per manuscript is allowed. Studies with more than eight authors should include a statement providing a reason for the inclusion of each author. In cases of collective (corporate) authorship, the group should identify the individuals taking direct responsibility for the manuscript. According to the Uniform Requirements, edited by the International Committee of Medical Journal Editors (ICMJE), “authorship credit should be based on: 1) substantial contributions to conception and design, acquisition of data, or analysis and interpretation of data; 2) drafting the article or revising it critically for important intellectual content; and 3) final approval of the version to be published. Authors should meet conditions 1, 2, and 3” (original text available at http://www.icmje.org/recommendations/browse/roles-and-responsibilities/defining-the-role-of-authors-and-contributors.html). Inclusion of authors’ names whose contributions do not fulfill these criteria is not recommended nor warranted. Also, authors’ names will be published in the exact order in which they appear in the title page of the original submission. The order of authors cannot be changed, and authors cannot be added or removed, after acceptance or during the production stage, unless a justification for such change, in writing, signed by all authors, is timely presented to the Editorial Office team. J Vasc Bras. publishes author contributions. A supplementary statement describing the specific contributions of each author to the study should be provided for each manuscript, as described in detail below.
6. Decision and translation - Authors will be informed of the acceptance of their articles via a decision letter sent by our submission system. This message is the official acceptance document issued by the Journal; no other documents will be issued with the same purpose. Once accepted, manuscripts will enter the production process (press) of J Vasc Bras. and will be published in a future issue, as decided by the Editor-in-Chief. Changes to the text or to author names will not be allowed at this stage. Manuscripts accepted in Portuguese or Spanish will be translated into English by the journal's production team, and the translation will be subjected to the corresponding author's approval; manuscripts accepted in English will be revised/copyedited by the journal's production team, and the final version will be subjected to the corresponding author's approval. The editorial office of the Journal will not provide information on the exact date of publication or on the issue in which the article will be published, since the contents of each issue are decided exclusively by the Editor-in-Chief.
7. Before publication, content proofs (in MS Word© DOCX file) and layout proofs (PDF file) are sent to the corresponding author for approval. Authors should download Acrobat Reader (http://get.adobe.com/br/reader/, download free of charge) to read the PDF file. Proof corrections should be limited to typesetting errors. No substantial changes will be accepted at this stage. Corrected proofs should be returned within 48 hours of receipt via e-mail. Once the production process of the PDF files is completed, the article will be sent to publication ahead of print at SciELO (http://www.scielo.br/jvb).
8. SECTION POLICIES
8.1. Original articles: J Vasc Bras. publishes complete original articles reporting the results of prospective, experimental, or retrospective studies, as well as articles awarded in congresses. These articles will be given priority for publication. They should be composed of: title page (submitted as a separate file), structured abstract (including the following sections: Background, Objectives, Methods, Results and Conclusions, with no more than 250 words) and keywords in English, structured abstract and keywords in Portuguese (if possible), text (Introduction, Methods, Results, Discussion or equivalent), acknowledgements (if applicable), references, tables (if applicable), figure legends (if applicable), and figures (if applicable). Original articles should not exceed 3,000 words (not including title page, abstract, tables, figures, and references) and 40 references.
8.2. Novel diagnostic, surgical, and clinical treatments: J Vasc Bras. publishes presentation of novel diagnostic, surgical, and clinical treatments, provided there are no clear or disguised commercial purposes or associations with pharmaceutical or medical device companies. They should be composed of: title page (submitted as a separate file), unstructured abstract (with no more than 150 words) and keywords in English, unstructured abstract and keywords in Portuguese (if possible), text, references, tables (if applicable), figure legends (if applicable), and figures (if applicable). Innovations should not exceed 3,000 words and 30 references.
8.3. Brief communications: J Vasc Bras. publishes brief communications, i.e., initial or preliminary and partial results of clinical or surgical studies under development, or reports on the application of an innovative technique. They should be composed of: title page (submitted as a separate file), unstructured abstract (with no more than 150 words) and keywords in English, unstructured abstract and keywords in Portuguese (if possible), text, references, tables (if applicable), figure legends (if applicable), and figures (if applicable). Brief communications should not exceed 1,500 words and 25 references.
8.4. Review articles: J Vasc Bras. publishes review articles, including meta- analyses and editorial comments. They should be composed of: title page (submitted as a separate file), unstructured abstract (with no more than 150 words) and keywords in English, unstructured abstract and keywords in Portuguese (if possible), text, references, tables (if applicable), figure legends (if applicable), and figures (if applicable). Review articles are allowed to have up to 5,000 words and 100 references.
8.5. Case reports: J Vasc Bras. publishes well-documented case reports, of great clinical interest. J Vasc Bras. will only accept cases reporting rare entities, pioneer or innovative treatments, or unexpected results. They should be composed of: title page (submitted as a separate file), unstructured abstract (including no more than 150 words) and keywords in English, unstructured abstract and keywords in Portuguese (if possible), text (Introduction, Case description and Discussion or equivalent), references, figure legends (if applicable), and figures (if applicable). Case reports should not exceed 1,500 words and 25 references.
8.6. Therapeutic challenge: J Vasc Bras. publishes therapeutic challenges, divided into four parts, as follows: 1) Introduction; 2) Part I - Clinical situation , describing the case or situation, including images and/or examinations performed, followed by pertinent questions regarding additional diagnostic means and/or therapeutic conducts; 3) Part II - What was done, describing the conduct of choice, including procedures (surgical or clinical), additional examinations, progress of follow-up (if applicable), etc.; 4) Discussion, including a final paragraph with the conclusions of the study. They should be composed of: title page (submitted as a separate file), abstract and keywords, in both Portuguese and English, if possible, text, references, tables, figure legends (if applicable), and figures (if applicable). Therapeutic challenges should not exceed 1,500 words and 25 references.
8.7. Dissertation abstracts: J Vasc Bras. publishes abstracts of dissertations presented and approved within 12 months prior to the submission date. They should be composed of: dissertation title, full name of the author, advisor, and members of the dissertation committee, date and service/department/program where the dissertation was developed and presented, abstract (main text), and keywords. Dissertation abstracts should be structured and have no more than 350 words.
8.8. Letters to the Editor: J Vasc Bras. publishes letters to the Editor concerning editorial subject or published articles. They should be composed of: title, name of the author (submitted separately), identification of the article commented, and references (if applicable). Letters to the Editor should have no more than 350 words.
8.9. Special Issues : J Vasc Bras. publishes annals of congresses, guidelines, collections of works presented at conferences sponsored by SBACV, and supplements focusing on specific topics may be organized upon request to the Editor-in-Chief. Book reviews may be published in J Vasc Bras. issues upon invitation and analysis of the Editor-in-Chief.
II. CONFLICT OF INTEREST, HUMAN AND ANIMAL RIGHTS, AND INFORMED CONSENT
1. Conflicts of interest and Funding information - J Vasc Bras. publishes Authors funding and conflict of interest disclosure statement. Authors must disclose, by means of a supplementary statement or along with each author’s name, any conflicts of interest that might bias, or in any way impact the integrity of, the submitted manuscript. Some examples include publications, public statements related to the subject of the manuscript, participation in an industry advisory committee, or other activities related to industry sources. Authors should use the list below as a criterion for the statement of potential conflicts of interest:
- to participate in clinical and/or experimental trials supported by a commercial entity;
- to participate in speaking activities related to industry sources;
- to be a consultant to or director of a commercial entity;
- to participate in an industry advisory committee receiving money for completion of research;
- to receive grant money from a commercial entity;
- to be a shareholder of a commercial entity;
- to have a family relationship with owners/directors of a commercial entity having an interest in the subject of the manuscript;
- to produce scientific reports in journals supported by a commercial entity;
- to have any financial relationship with people and institutions that might affect the integrity of the manuscript (e.g., being an employee, consultant or shareholder of a commercial entity, receiving honoraria, providing expert testimony, holding patent rights or having a patent application pending, receiving grants or other types of financial support).
- positive or negative impact on cited companies or products/patents involved in the research.
Note: the ICMJE Conflicts of Interest PDF Form must be used as the basis for this statement and must be completed by all authors (http://www.icmje.org/coi_instructions.html).
2. Ethics committee - A statement concerning approval of the study by the institutional research ethics committee (or equivalent) should be included with the manuscript. International authors should state that the manuscript is in accordance with the Helsinki Declaration and with local ethical guidelines. Informed consent should be obtained where appropriate, and this should be clearly indicated in the article. The authors should keep copies of informed consent forms and other documents required by the Ethics Committee at the institution in which the work was carried out. Animal experiments should conform with guidelines applicable to the corresponding type of study.
3. Registration of Clinical Trials - J Vasc Bras. supports the policy of registration of clinical trials by the World Health Organization (WHO) and the ICMJE, recognizing the importance of such initiatives for registration and public access to information on clinical trials. According to this recommendation, clinical trials should be registered in one of the Clinical Trials Registries recommended by the WHO and the ICMJE. Addresses are available at the ICMJE website (e.g., www.clinicaltrials.gov, www.ISRCTN.org, www.umin.ac.jp/ctr/index.htm e www.trialregister.nl). In Brazil, clinical trials can be registered on www. ensaiosclinicos.gov.br. To this end, the first requirement is to obtain a registration number for the study, named UTN (Universal Trial Number), at the link http://www.who.int/ictrp/unambiguous_identification/utn/en/ and also import the xml file of the study registered at Plataforma Brasil (http://aplicacao.saude.gov.br/plataformabrasil/login.jsf). The clinical trial registration number should appear in a statement below the abstract. All manuscripts resulting from randomized clinical trials should have a clinical trial registration number.
|
|
